The latest from French writer-director Vladimir de Fontenay tracks a father (Swann Arlaud) and son stranded together in the Nordic wilderness. By Jordan Mintzer Movies about irresponsible ...

Leerink analyst Joseph Schwartz notes Outperform-rated Sarepta (SRPT) disclosed two-year Part 1 and one-year Part 2 data from the EMBARK study with Elevidys. The firm views these topline results ...

Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Don Swann was an important American printmaker. Known for his detailed depictions of colonial and Neo-classical American architecture, his artworks serve as both important historical documents and ...

Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of $0.11 for the quarter, up from their previous forecast of $0.02.

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against the other ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against the other medical AI ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...